Online inquiry

IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15434MR)

This product GTTS-WQ15434MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15434MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8332MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ15302MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ5118MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ13996MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10795MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ14647MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ4125MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ7544MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-182
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW